FARMACOLOGIA ANTIULCEROSOS PDF

Con efecto antisecretor y protector de la mucosa prostaglandinas, acexamato de cinc ; 4. Protectores de la mucosa sucralfato, carbenoxolona, sales de bismuto. Anti-peptic ulcer agents aim to achieve the relieve of symptoms, the healing of the ulcer and to avoid recurrences and complications. We can define four classes of anti-ulcer drugs according to their mechanisms of action: 1. Gastric acidity inhibitors antiacid agents ; 2.

Author:Taulabar Mezil
Country:Gabon
Language:English (Spanish)
Genre:History
Published (Last):14 September 2006
Pages:335
PDF File Size:2.4 Mb
ePub File Size:14.92 Mb
ISBN:908-4-71835-788-3
Downloads:2950
Price:Free* [*Free Regsitration Required]
Uploader:Akirg



Con efecto antisecretor y protector de la mucosa prostaglandinas, acexamato de cinc ; 4. Protectores de la mucosa sucralfato, carbenoxolona, sales de bismuto. Servicio de Urgencias. Hospital Mutua de Terrassa. Robert 5. S2 nti-peptic ulcer agents aim to achieve the relieve of symptoms, the healing of the ulcer and to avoid recurrences and complications.

We can define four classes of anti-ulcer drugs according to their mechanisms of action: 1. Gastric acidity inhibitors antiacid agents ; 2. Gastric acid secretion inhibitors antiH2-, antimuscarineand antigastrin agents, proton pump inhibitors and somatostatin analogues ; 3. Drugs with mucous antisecretory and protective effect prostaglandins, zinc acesamate ; 4.

Drugs with mucous protective effect sucralphate, carbenoxalone, bismuth salts. A review of action mechanisms, indications and adverse side effects is performed. Several currently available intravenous drugs of this classes, which can be used in emergency conditions, as high digestive system hemorrhage, are described.

Muchos autores desaconsejan su empleo. Potencial interferencia con el metabolismo de otras drogas p. Pocas interferencias descritas. Efecto antisecretor prolongado mayor que la de los anti-H2 pero menor que omeprazol No es preciso ajustar dosis si existe insuf. Contraindicado en embarazo. Los pacientes con insuficiencia renal pueden padecer intoxicaciones debidas al magnesio y al aluminio. Las sales de aluminio y calcio son astringentes.

Todos son excretados fundamentalmente por la orina En los pacientes con insuficiencia renal es necesario reducir las dosis Las diferencias entre los medicamentos del grupo no son importantes. Esta prevalencia es similar a la observada en pacientes tratados con placebo, lo que indica que el tratamiento con antagonistas de los receptores H2 de la histamina no modifica la historia natural de la enfermedad ulcerosa4,, A diferencia de los antagonistas H2, no es preciso ajustar la dosis en pacientes con insuficiencia renal.

Estas diferencias son menores o no son significativas a las semanas de tratamiento4, Cuando se utiliza en monoterapia, el omeprazol tiene un efecto supresor sobre el H. Algunos estudios sugieren que el lansoprazol puede tener un efecto antimicrobiano superior al del omeprazol contra el H. En humanos no se han observado lesiones premalignas y estos cambios en ratas no son considerados como relevantes para las personas.

Mien- S. La eficacia de un tratamiento de mantenimiento con prostaglandinas no es conocido. Es posible encontrar presentaciones de misoprostol combinadas con diclofenac. No se ha demostrado teratogenicidad. Gut ; Peptic ulcer and related disorders. New York. McGraw-Hill En: Farreras Rozman. Tratado de Medicina Interna. Barcelona: Mosby-Doyma, Auckland: Adis International ed. Healing of duodenal ulcer with an antacid regimen.

N Engl J Med ; Antacids: the past, present and future. Peptic ulceration. The milk aIkali syndrome. Am J Dig Dis ; The diagnostic importance of hypophosphatemia. Med Times ; Evidence for a phospho-rus-depletion syndrome in man.

Effect of food and antacid on binding of sucralfate to normal and ulcerated gastric and duodenal mucosa in rats. J Clin Gastroenterol ;3 Suppl 2 Effects of sucralfate or mild irritants on experimental gastritis and prostaglandin production. Am J Med ; Drug interactions. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Drugs ; Famotidine: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Nizatidine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Roxatidine acetate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.

Pharmacokinetic optimisation of the treatment of peptic ulcer to patients with renal failure. Clinical Pharmacokinetics ; Controlled therapautic trial to determine the optimum dose of antacids to duodenal ulcer. A consideration of the adverse effects of cimetidine. Gastroenterology ; A comparative overview of the adverse effects of antiulcer drugs.

Drug Safety ; Pirenzepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer diseases and other allied diseases. Clinical and pharmacological properties of pirenzepina. Peptic ulcer disease: advances to pathogenesis and treatment. New York: Raven Press, ; Clinical results with pirenzepine. New York: Raven Press, Omeprazole: an update uf its pharmacology and therapeutic use in acid-related disorders.

Pantoprazole: a review of its pharmaco- S. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties. Drugs ; Eur J of Gastroenterol Hepatol ; Tratamiento erradicador de Helicobacter pylori.

Rabeprazole Study Group. Am J Gastroenterol ; Prostaglandins in peptic ulcer disease: an overview of current status and future directions. Cytoprotection by prostaglandins. Drugs Aging ; Misoprostol: a preliminary re-view of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of peptic ulcer disease.

Med Clin Barc ; Sucralfate: a review of its pharmacological properties and therapeutic use in peptic ulcer disease. Development and characteristics of sucralfate.

Selective binding of sucralfate to ulcer lesion I. Experiments in rats with acetic acid induced gastric ulcer receiving unlabelled sucralfate. Arzneimittelforschung ; Sucralfate: pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animal. Safety experience with sucralfate in Japan.

Clin Gastroenterol ; 3 Suppl 2 Sucralfate and warfarin [letter]. Ann Intern Med ; S13 Documentos relacionados.

ELECTRONIC COMMUNICATIONS DENNIS RODDY JOHN COOLEN PDF

ANTIULCEROSOS 22

Por el mecanismo de accin se pueden distinguir cuatro grupos: 1. Inhibidores de la acidez gstrica anticidos ; 2. Inhibidoresde la secrecin gstrica anti-H2, antimuscarnicos,antigastrinas, inhibidores de la bomba de protones y agonistasde la somatostatina ; 3. Con efecto antisecretor y protector de la mucosa prostaglandinas, acexamato decinc ; 4.

ELECTRO VOICE TX1152 PDF

FarmacologĂ­a De Los Antiulcerosos

Con efecto antisecretor y protector de la mucosa prostaglandinas, acexamato de cinc ; 4. Protectores de la mucosa sucralfato, carbenoxolona, sales de bismuto. Servicio de Urgencias. Hospital Mutua de Terrassa. Robert 5. S2 nti-peptic ulcer agents aim to achieve the relieve of symptoms, the healing of the ulcer and to avoid recurrences and complications.

DENON DN-V300 PDF

CategorĂ­a:Antiulcerosos

Antagonistas H2: cuotas de mercado en valores de los principales productos Fig. Inhibidores de la bomba de protones: principales marcas cuotas de mercado en valores Tabla. Inhibidores de la bomba de protones: principales laboratorios Fig. El volumen de cada uno de los subgrupos puede apreciarse en las figuras 1 y 2. En ellas queda reflejado el uso mayoritario, como ya se ha comentado, de los antiulcerosos. El tercero es Altana Pharma, con

DESERT DAWN WARIS DIRIE PDF

ANTI ACIDOS E ANTI ULCEROSOS

.

Related Articles